PCOS Skin, Hair, and Acne: What They Tell You About Fertility

You are dealing with chin hair you keep tweezing, a hairline that is creeping back, and acne that flares along your jaw before a period that might or might not arrive. You have heard "it is just hormones" your whole adult life. Now you are trying to conceive, and you want to know what these specific symptoms actually mean about what is happening inside.

Hirsutism, scalp hair thinning, and adult acne are not cosmetic side-quests. They are clinical signals of androgen and insulin biology that quietly predict how your ovulation, your cycle response to medication, and your fertility timeline are likely to behave. The hair follicle and the sebaceous gland are end-organs for androgens. What shows up on your face and scalp is mirroring what is shaping your follicular environment.

The 2023 International PCOS Guideline names clinical hyperandrogenism (hirsutism, acne, and female-pattern hair loss) as one of the three Rotterdam criteria for diagnosis, and recognises it as one of the most accessible markers of androgen excess in clinic.¹ For many people, what you can see on the body is the cheapest, fastest, and most honest hormone test there is. Bloods like a free testosterone, SHBG, or FSH fill out the picture. The question of what an FSH test tells you comes up often here, and we will get to where it fits below. The visible signs still do real diagnostic work on their own.

Why skin and hair are fertility signals, not just cosmetic ones

Severity of these visible signs correlates loosely but meaningfully with severity of ovarian androgen drive, and with how stubborn anovulation is likely to be to treat. A modified Ferriman-Gallwey (mFG) hirsutism score that creeps higher tends to track with a higher free androgen index and a higher likelihood that letrozole will outperform clomiphene for ovulation induction.³ The skin signs do not just describe a cosmetic burden; they help me predict the cycle response.

This is also why I do not promise that fertility treatment will resolve the cosmetic features. It usually will not, in most cases. The follicles on your face that have already gone terminal stay terminal even when androgens come down. Treatment is about preventing new hair, not erasing old hair, and being honest about that up front matters.

Hirsutism, what it is and what it predicts

Hirsutism is terminal, dark, coarse hair in a male-pattern distribution. It is quantified with the modified Ferriman-Gallwey score, which rates nine body areas from 0 to 4 each. The 2023 Teede Guideline updated the clinically significant cutoff to roughly 4 to 6 depending on ethnicity, lower than older thresholds.^{1 6} Common sites are the upper lip, the chin, around the areola, the mid-chest, the lower abdominal midline, the lower back, and the inner thighs.

What hirsutism predicts is ongoing androgen production, either ovarian or adrenal. Higher mFG correlates with higher free testosterone, lower SHBG, and a higher likelihood of needing letrozole rather than clomiphene to ovulate.³ What it does not predict reliably is how quickly the hair itself will resolve with any treatment. Hair-removal strategies and cycle treatment run on different timelines, and that is worth saying out loud at the start.

When I assess hirsutism, I ask the clinician to document the mFG and to record the score in the notes. Tracking it over time is the only way to see whether an intervention is moving the underlying biology.

Female-pattern hair loss in PCOS

The scalp pattern in PCOS is female-pattern hair loss, also called female androgenetic alopecia. It is diffuse thinning across the crown and a widening central part, with the frontal hairline usually preserved. This is different from male-pattern bitemporal recession. The mechanism is the same one as in male androgenetic alopecia (terminal scalp follicles miniaturising under chronic androgen exposure), just with a different distribution and a slower trajectory.

Before I attribute scalp thinning to PCOS, I rule out the differentials, because misdiagnosis is common. Iron deficiency (ferritin under 30 ng/mL is the threshold I use clinically for hair-related symptoms, even when haemoglobin is normal), thyroid disease (TSH and free T4, plus TPO antibodies if there is a personal or family history), telogen effluvium after a major stressor or postpartum, and alopecia areata all sit on the differential. Treating PCOS as the cause when one of these is the actual driver delays the right answer.

For the TTC reader, the practical limit is this: the medications that are first-line for female androgenetic alopecia outside pregnancy (oral spironolactone, oral finasteride) are not pregnancy-compatible and are not used while you are actively trying to conceive. Topical minoxidil at 2% or 5% is the option that remains on the table, and even minoxidil is typically paused around conception. The honest version of this conversation acknowledges that hair-loss treatment and fertility treatment are not happening in parallel; they take turns.

PCOS acne, and what makes it different

PCOS acne does not look like teenage acne. The distribution is jawline, chin, sometimes the neck and upper back. The lesions are inflammatory papules and nodules more than blackheads or whiteheads. The timing classically follows a premenstrual flare, though for many people with PCOS, cycles are irregular enough that the cyclical pattern is hard to spot.

The driver is increased sebum production under androgen stimulation, layered with insulin-driven IGF-1 effects on the sebaceous gland.² So PCOS acne tends to respond when you address both androgens and insulin, not just topical care.

The TTC-compatible toolkit is narrower than the general dermatology toolkit. Topical azelaic acid, topical clindamycin, and gentle salicylic acid in low concentrations are usually acceptable in someone actively trying to conceive, with a derm confirming the specific product. Topical retinoids and oral isotretinoin are not used in TTC because of teratogenic concern. Oral spironolactone, which is effective for hormonal acne in non-pregnant adults, is stopped before TTC; it is teratogenic in the first trimester. The combined contraceptive pill, which suppresses acne by suppressing androgens, is obviously off the table for someone trying to conceive.

Realistic expectations: acne tends to improve, sometimes meaningfully, when ovulation is restored and insulin biology is addressed. It does not vanish, and treatment of acne does not run on the same clock as your cycle plan.

Acanthosis nigricans, the marker most people miss

Acanthosis nigricans is the dark, velvety, sometimes thickened skin that appears at the nape of the neck, in the axillae, in the groin, and occasionally on the knuckles. It is often mistaken for being unwashed and scrubbed at, sometimes for years, which does nothing except irritate the skin. It is a near-pathognomonic skin sign of hyperinsulinaemia.³

When I see acanthosis nigricans on someone with a PCOS workup in progress, my pre-test probability that insulin resistance is their dominant driver goes up sharply. The clinical implication is twofold. First, it changes the fertility plan: people with acanthosis nigricans tend to benefit from metformin or inositol as adjuncts to ovulation induction. Second, it changes the pregnancy plan: they are also more likely to develop gestational diabetes, so the metabolic groundwork done in the preconception window matters.

This is one of the most under-checked physical signs in routine workups. If you have it, point it out specifically. If your clinician has not commented on it, ask.

What labs to ask for when skin and hair are the loudest symptom

When the visible androgen excess is the dominant presenting feature, the lab workup needs to match it. The bloods I ask for are:

• Total testosterone, free testosterone, and SHBG (to calculate the free androgen index)
• Androstenedione
• DHEAS, to distinguish adrenal from ovarian androgen sources
• 17-hydroxyprogesterone, drawn in the early morning and ideally in the early follicular phase, to rule out non-classical congenital adrenal hyperplasia⁵
• Fasting insulin and HOMA-IR, plus HbA1c, because skin signs predict insulin biology
• Ferritin, TSH, and free T4, to rule out competing causes of hair loss
• Prolactin, to rule out a pituitary cause of cycle disruption

People often ask where FSH fits in this picture, since FSH is one of the labs that shows up on every fertility blood form. The short version: what an FSH test tells you in a PCOS workup is information about pituitary signalling and ovarian reserve, not about androgen excess directly. In PCOS, FSH is often low-normal and LH is elevated, which gives the LH:FSH ratio that tilts toward LH. The skin and hair signs are not what an FSH test is measuring; they are downstream of androgen production, not of the pituitary signal itself. We run FSH anyway as part of the broader cycle workup.

How these signs change the fertility plan

Once the visible signs and the labs are on the table, they shape the plan in specific ways. A high mFG paired with a high free testosterone makes me lean letrozole over clomiphene for ovulation induction. The PALO trial established that letrozole outperformed clomiphene for live birth in PCOS, and the hyperandrogenic phenotype is part of why that difference exists.³

Acanthosis nigricans or an elevated fasting insulin pushes me to add inositol or metformin to the cycle plan, and to extend that into the preconception window for pregnancy outcomes, not just ovulation. Predominant scalp loss with a normal ovarian androgen panel but a high DHEAS pulls me toward thinking about an adrenal-dominant pattern, which means a 17-hydroxyprogesterone has to be on the file before I commit to that label.⁵

The signs that take us out of routine PCOS work and into urgent endocrine review are rapidly progressive hirsutism, virilisation, voice deepening, or a male-pattern muscle gain. These need imaging and an androgen-secreting tumour workup, not a PCOS supplement protocol. The pace matters: PCOS hirsutism builds slowly over years. A six-month doubling of hair growth is not garden-variety PCOS.

What's normal, what's a red flag

What is normal is a hair or two on the chin, mild jawline acne, slight central scalp thinning that has developed over years, and an mFG that hovers in the low single digits. Common, manageable, and consistent with PCOS.

What is a red flag is voice deepening, clitoromegaly, hirsutism that has visibly worsened in six months rather than years, and rapid male-pattern muscle gain. These are signs that need urgent endocrine review rather than another cycle of waiting.

A second red-flag pattern to know about: a very high DHEAS, especially paired with a 17-OHP above 200 ng/dL or a known family history of CAH, points toward non-classical congenital adrenal hyperplasia rather than PCOS.⁵ The workup is different; the diagnosis is different.

What to ask before your next appointment

A short list, designed to get the workup detailed enough to actually guide treatment.

1. "Will you score my modified Ferriman-Gallwey and document it so we can track response to treatment?"
2. "Can we measure free testosterone and SHBG, not just total testosterone?"
3. "Given the acanthosis at my neck, are we addressing insulin alongside ovulation?"
4. "Have we run a 17-hydroxyprogesterone to rule out non-classical congenital adrenal hyperplasia?"
5. "If we start letrozole, what is realistic to expect for the acne and the hair?"

What's next

• If you have not yet read the phenotype pillar: The four PCOS types: insulin, inflammatory, adrenal, post-pill
• If you are pre-treatment and setting up the preconception window: Preconception supplement stack
• If insulin is the dominant signal: Inositol and metformin for PCOS
• If you want to understand the pregnancy implications of an insulin-driven picture: PCOS pregnancy risks: gestational diabetes and hypertension

Sources

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025.
2. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology 2018;14(5):270-284. https://doi.org/10.1038/nrendo.2018.24.
3. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://doi.org/10.1056/NEJMoa1313517.
4. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertility and Sterility 2006;86 Suppl 1:S7-S8. https://doi.org/10.1016/j.fertnstert.2006.03.012.
5. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2018;103(11):4043-4088. https://doi.org/10.1210/jc.2018-01865.
6. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Human Reproduction Update 2010;16(1):51-64. https://doi.org/10.1093/humupd/dmp024.